-
ESMO Immuno-oncology Conference 2021 announces the latest data on the combination therapy of Sofantinib and Teriplizumab
Time of Update: 2021-12-30
gov registration number NCT02588170) of Sofatinib in the treatment of patients with advanced non-pancreatic neuroendocrine tumors .
gov registration number NCT02589821) of Sofatinib for the treatment of patients with advanced pancreatic neuroendocrine tumors .
-
A multi-institution retrospective analysis of central nervous system recurrence of ASHT cell lymphoma in 2021
Time of Update: 2021-12-30
Research background Studies have identified risk factors for recurrence of the central nervous system (CNS) in patients with lymphoma, such as high tumor burden and extranodal (EN) disease .
-
One article summarizes the key points of cancer pain treatment
Time of Update: 2021-12-30
Cancer pain analgesic drug classification principle 01 non-steroidal drugs commonly used in the treatment of cancer pain, non-steroidal anti-inflammatory agents include: ibuprofen, diclofenac, acetaminophen, indomethacin, celecoxib and the like .
-
Review of oncolytic viruses: the latest frontier in cancer immunotherapy
Time of Update: 2021-12-29
Although processing OVs through different methods can enhance oncolytic activity and activate anti-tumor immune responses, it has been reported that OVs are more effective when used in combination with other cancer treatments (such as chemotherapy, radiotherapy, immunotherapy or cell therapy) .
-
One cycle of immunization + chemotherapy, the elderly patients with lung squamous cell carcinoma develop purulent pericarditis, whose "pot" is it?
Time of Update: 2021-12-29
The patient’s current diagnosis includes: right lung cancer (squamous cell carcinoma, T2N3M0, stage IIIB), bone marrow suppression after chemotherapy, purulent pericarditis, type I respiratory failure, liver and kidney cardiac insufficiency, atrial fibrillation, hypothyroidism, diarrhea, and electrolyte imbalance .
-
Immunologic drugs help first-line treatment benefits for patients with advanced colorectal cancer, domestic PD-L1 inhibitors bring new treatment options
Time of Update: 2021-12-29
In the pivotal phase II study of envolimab [2], the objective response rate of envolimab as a single agent (administered at 150 mg QW) for 65 patients with MSI-H/dMMR colorectal cancer as second-line treatment (ORR) is 43.
-
A team of Chinese scientists: Baicalein is expected to be used in a new type of targeted therapy for colorectal cancer
Time of Update: 2021-12-29
In this study, the researchers used colorectal cancer cells as a research model, performed drug-target-disease network analysis, and constructed a protein-protein interaction network to explore the downstream of TLR4 that mediates the inhibitory effect of baicalein Signal molecule .
-
Professor Cao Junning, the new "power" of ASH: Focusing on the research data of the double antibody Mosunetuzumab in the treatment of FL, innovative therapies, the future can be expected!
Time of Update: 2021-12-29
Figure 2 The occurrence of CRS in 3L+R/R FL patients treated with Mosun monotherapy [Oral 129] Mosun combined with lenalidomide regimen is safe and controllable for patients with R/R FL who have previously received ≥1 line therapy, and the effect is good.
-
Dong Yizhou’s team developed biomimetic nanoparticles to deliver mRNA to enhance cancer immunotherapy
Time of Update: 2021-12-29
Agonistic antibodies against costimulatory receptors can enhance anti-tumor T cell immunity and have been used in cancer treatment .
In this study, PL1 nanoparticles were used to deliver OX40 mRNA to tumor-infiltrating T cells, increasing the expression of OX40, thereby enhancing the anti-tumor effect of anti-OX40 antibodies .
-
ATG-101 clinical trial completes first patient dosing in Australia
Time of Update: 2021-12-29
As a new PD-L1/4-1BB bispecific antibody, ATG-101 can block the immunosuppressive PD-L1/PD-1 binding and conditionally activate the 4-1BB costimulatory signal, thereby activating anti-tumor Immune effector cells enhance the safety while enhancing the efficacy of the drug .
-
A list of recommended guidelines for colorectal cancer screening and early diagnosis and treatment!
Time of Update: 2021-12-29
➤The initial age of colonoscopy screening for high-risk populations with Lynch syndrome caused by MSH6/PMS2 mutations is 30-35 years or 2 to 5 years earlier than the age of onset of the youngest patient in the family (strong recommendation, GRADE evidence classification: Low) .
-
Multidisciplinary teams work closely together to help breast cancer patients manage the entire process
Time of Update: 2021-12-29
After learning about this situation, the Department of Pharmacy actively paid attention to the problem of'remaining fluid management' of trastuzumab, and recently introduced specifications for The domestic small-strength trastuzumab of 150mg and 60mg can achieve'ready-to-use', without the need for'surplus liquid management', to ensure the convenience and safety of the medication process, and to ensure the standardization of clinical treatment of breast cancer .
-
Express congratulations!
Time of Update: 2021-12-29
BridGene's unique IMTAC technology platform can not only find small molecule ligands for a large number of targets (including "non-drugable" targets) in living cells; it can also be combined with phenotypic screening technology to determine targets that drive phenotypic changes and disease occurrence .
-
Professor Fang Luo: Based on standardized medication, explore the way to optimize the medical quality of cancer patients
Time of Update: 2021-12-29
Multi-dimensional consideration of standardized medications and comprehensive improvement of patient medical quality Professor Fang Luo pointed out that in recent years, the growth of new anti-tumor drugs has not only brought more and better choices for clinical treatment, but also proposed reasonable and standardized medications for clinical treatment.
-
Miduoline combined with first-line chemotherapy can reduce the cumulative recurrence rate of AML patients with FLT3 mutation
Time of Update: 2021-12-29
The results of a prospective, international multicenter, randomized, double-blind, placebo-controlled clinical trial (CALGB10603/RATIFY) showed that in AML patients with FLT3 mutations, standard first-line chemotherapy can be improved by adding midostaurin The overall survival (OS) of the patient .
-
The world's first first-line treatment of SCLC with positive results of PD-1 inhibitor data announced!
Time of Update: 2021-12-29
The ASTRUM-005 study is a randomized, double-blind, international multi-center, phase III clinical study that evaluated slulimumab and placebo combined with chemotherapy for the treatment of previously untreated extensive-stage small cell lung cancer (ES-SCLC) Patient effectiveness and safety .
-
Nerve-sparing radical resection of prostate cancer-easily say goodbye to urine leakage and return to a better life
Time of Update: 2021-12-29
Nerve-sparing radical prostatectomy for prostate cancer-"new breakthrough" For the above-mentioned patients who have greater concerns about postoperative complications, our team at the Department of Urology, Zhongshan Hospital recommends a 3-D laparoscopic clinically advanced prostate with nerve-sparing prostate Radical cancer surgery, the advantage of this surgery is that it can minimize urine leakage after surgery and preserve sexual function .
-
Another new cancer drug approved in China!
Time of Update: 2021-12-29
In recent years, with the development of proteasome inhibitors, immunomodulators, anti-CD38 monoclonal antibodies, CAR-T cell therapy, autologous hematopoietic stem cell transplantation and other therapeutic methods, as well as the application of combined treatment programs, the treatment of multiple myeloma It has been perfected and improved, and the patient's survival period has been significantly prolonged .
-
New drug development Arnold Pharma's oral PD-L1 inhibitor AN4005 is approved by NMPA to start clinical trials
Time of Update: 2021-12-29
He Nanhai, head of Arnold Pharma's global research and development, said: As a small molecule PD-L1 inhibitor, AN4005 has shown good anti-tumor activity, and it will have a huge future in monotherapy and combination with other products of the company.
-
Molecular Cancer Sichuan University Peng Yong/Zhu Xiaofeng/Zhou Liangxue systematically characterized the genetic change spectrum of craniopharyngioma
Time of Update: 2021-12-29
On December 18, 2021, Peng Yong, Zhu Xiaofeng, and Zhou Liangxue of Sichuan University published an online research paper entitled "Characterization of novel CTNNB1 mutation in Craniopharyngioma by whole-genome sequencing" in Molecular Cancer (IF=27).
In addition, the study confirmed that CTNNB1 and BRAF V600E mutations are mutually exclusive in ACP and PCP, respectively .
